NASDAQ·Biological Products, (No Diagnostic Substances)
RXRX
RECURSION PHARMACEUTICALS, INC.
RECURSION PHARMACEUTICALS, INC. (ticker: RXRX) is an NASDAQ-listed biological products, (no diagnostic substances) company. DredgeCap's structured extraction of RXRX's SEC filings surfaces 1 active risk signal, including 1 auditor-change signal. RXRX reported $6.47M in revenue and -$117.50M for the period ending 2026-03-31, with operating cash flow of -$81.10M. Cash and equivalents stood at $654.47M (up 30.8% year-over-year). Total assets of $1.34B exceed total liabilities of $314.75M. Each signal on this page is sourced verbatim from the underlying SEC filing. Use the tabs above to drill into auditor history, going-concern citations, dilution mechanics, cash runway, and the full risk-flag inventory.
RXRX Legal Proceedings
DredgeCap has not located any disclosed legal proceedings for RECURSION PHARMACEUTICALS, INC. (RXRX) in the SEC filings currently cached or in the federal-court records searched. 0 periodic filings reviewed, 0 with specific disclosure content. The absence of records here does not certify that the company is free of litigation — coverage reflects only what DredgeCap has cached.